Milan Z, Taylor C, Armstrong D, Davies P, Roberts S, Rupnik B, Suddle A
Leeds Teaching Hospital, Leeds, United Kingdom; now at King's College Hospital, London, United Kingdom.
School of Mathematics, University of Leeds, Leeds, United Kingdom.
Transplant Proc. 2016 Jan-Feb;48(1):111-5. doi: 10.1016/j.transproceed.2015.12.027.
We compared the intraoperative hemodynamic profiles and outcomes of liver transplant (LT) patients receiving preoperative beta-blockers for portal hypertension with those of patients not receiving beta-blockers.
Beat-to-beat hemodynamic data were recorded with the use of a lithium dilution cardiac output monitor, including heart rate (HR), cardiac output (CO), cardiac index (CI), systemic vascular resistance (SVR), SVR index, mean arterial pressure, stroke volume (SV), and SV index. Perioperative data included age, sex, etiology of cirrhosis, Model of End-Stage Liver Disease score, warm and cold ischemia times, and intraoperative blood and blood products replacement. Postoperative data included Acute Physiology and Chronic Health Evaluation II score, Intensive Care National Audit and Research Centre (ICNARC) score, length of intensive care unit stay, renal replacement treatment, and mortality.
After exclusion, 215 patients not receiving and 93 patients receiving beta-blockers for portal hypertension were included. There was no significant difference between groups in demographic data. HR, CO, and CI were significantly lower in the beta-blocker group (P = .0001). Regarding outcomes, the ICNARC score was significantly higher in the beta-blocker group (P < .05).
Preoperative administration of beta-blockers attenuates the hyperdynamic circulation in LT patients; this is clearly seen through a reduction in intraoperative CO, CI, and HR. This decreased hyperdynamic state was not shown to relate to outcomes in any of the variables except for a higher ICNARC score reported in the group treated with beta-blockers.
我们比较了术前接受β受体阻滞剂治疗门静脉高压的肝移植(LT)患者与未接受β受体阻滞剂治疗的患者的术中血流动力学特征及预后。
使用锂稀释心输出量监测仪记录逐搏血流动力学数据,包括心率(HR)、心输出量(CO)、心脏指数(CI)、全身血管阻力(SVR)、SVR指数、平均动脉压、每搏量(SV)和SV指数。围手术期数据包括年龄、性别、肝硬化病因、终末期肝病模型评分、热缺血和冷缺血时间以及术中血液和血液制品输注量。术后数据包括急性生理与慢性健康状况评分系统II评分、重症监护国家审计与研究中心(ICNARC)评分、重症监护病房住院时间、肾脏替代治疗及死亡率。
排除后,纳入215例未接受β受体阻滞剂治疗的患者和93例接受β受体阻滞剂治疗门静脉高压的患者。两组患者的人口统计学数据无显著差异。β受体阻滞剂组的HR、CO和CI显著较低(P = .0001)。关于预后,β受体阻滞剂组的ICNARC评分显著较高(P < .05)。
术前给予β受体阻滞剂可减轻LT患者的高动力循环;这在术中CO、CI和HR降低中明显可见。除β受体阻滞剂治疗组报告的ICNARC评分较高外,这种降低的高动力状态与任何变量的预后均无关联。